30 results about "Bone Marrow-Derived Cell" patented technology

Studies have been made on a possibility that a bone-marrow-derived cell is recruited from an extracutaneous tissue into a skin graft during the process of adhesion of the skin graft to a biological tissue and therefore contributes to the regeneration of a skin tissue. As a result, the following facts 1) to 4) are found: 1) a large quantity of bone-marrow-derived cells are recruited into a skin graft; 2) the recruited bone-marrow-derived cells are differentiated into all of dermal fibroblasts, adipocytes, muscle cells, vascular endothelial cells and epidermal keratinocytes in the skin graft, and bone-marrow-derived mesenchymal stem cells are contained in the recruited bone-marrow-derived cells; 3) the substances which recruit the bone-marrow-derived mesenchymal stem cells from the peripheral blood into the skin graft are S100A8 and S100A9 which are released from a dead tissue in the skin graft; and 4) purified S100A8 and S100A9 can promote the migration of a mesenchymal stem cell which has been separated from a bone marrow and cultured.

The present invention is directed to a method of inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation and to a method of preventing metastases. These methods involve administering to the cancer patient an inhibitor of vascular endothelial growth factor receptor 1+ bone marrow-derived cells under conditions effective either to inhibit tumor formation in the cancer patient at a site remote from sites of prior tumor formation or to prevent metastases. Candidate compounds useful for such purposes can be screened depending on whether they bind to vascular endothelial growth factor receptor 1+ bone marrow-derived cells. Metastases in a cancer patient can be monitored by evaluating a patient sample for detection and quantification of vascular endothelial growth factor receptor 1+ bone marrow-derived cells and comparing the level of vascular endothelial growth factor receptor 1+ bone marrow-derived cells to prior levels.

The present disclosure relates to a method for introducing a hematopoietic cell into the brain of a mammal, by administering bone marrow-derived progenitor cells into the body of the mammal by intravenous injection. The bone marrow-derived cell is preferably a cell that differentiates into a glial cell. The disclosure also relates to a method for delivery of therapeutic protein molecules into the brain of a mammal, by administering to a mammal an effective amount of bone marrow-derived progenitor cells which contain a gene having a nucleic acid sequence that encodes a functional therapeutic protein. Isolated recombinant cells and a pharmaceutical composition are also provided.

The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.

The subject invention provides methods for recruitment of bone marrow-derived cells, including bone marrow-derived endothelial cells (BMDEC), and increasing their function by administration of relaxin. The methods of the invention can be used in, for example, treating conditions amenable to treatment by recruitment of bone marrow-derived cells, such as BMDEC and bone marrow-derived angio-osteogcnic progenitor cell.

The invention provides a preparation method of a medical cartilage support material. The preparation method comprises the following operation steps of: pretreatment, separation and primary washing of a cartilage tissue, inactivation of virus, decellularization, sodium chloride treatment, forming, and packaging and sterilization. The bone marrow-derived cell component and DNA (Deoxyribonucleic Acid) component of an animal are completely removed from the medical cartilage support material prepared by the method, meanwhile a natural ECM (Extracellular Cell Matrix) component and a three-dimensional are completely remained, and no endotoxin, organic solvent and toxic solvent are left; the medical cartilage support material has a porosity suitable for cell ingrowth and cartilage tissue regeneration, and also has ideal mechanical properties.